Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis

References

• Hay CR, Colvin BT, Ludlam CA, et al. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagul Fibrinolysis 1996;7:134-8
   PubMed Web of Science ®Google Scholar
• Lusher J, Ingerslev J, Roberts H, et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998;9:119-28
   PubMed Web of Science ®Google Scholar
• Lloyd Jones M, Wight J, Paisley S, et al. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003;9:464-520
   PubMed Web of Science ®Google Scholar
• Lechner K, Nowotny C, Krinninger B, et al. Effect of treatment with activated prothrombin concentrate (FEIBA) on factor VIII-antibody level. Thromb Haemost 1979;40:478-85
   PubMed Web of Science ®Google Scholar
• Hilgartner MW, Knatterud GL. The use of factor eight inhibitor bypassing activity (FEIBA immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood 1983;61:36-40
   PubMed Web of Science ®Google Scholar
• Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilisation of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997;77:1113-19
   PubMed Web of Science ®Google Scholar
• Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis 1998;9 (Suppl. 1):S93-5
   PubMed Web of Science ®Google Scholar
• Odeyemi IAO, Guest JF. Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK. J Med Econ 2002;5:119-33
   Google Scholar
• Odeyemi IAO, Guest JF. Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK. J Med Econ 2002;5:51-64
   Google Scholar
• Knight C, Paisley S, Wight J, et al. Economic modelling of different treatment strategies for haemophilia A with high responding inhibitors. Haemophilia 2003;9:521-40
   PubMed Web of Science ®Google Scholar
• Hilgartner M, Aledort L, Andes A, et al. and the Members of the FEIBA study group. Efficacy and safety of vapour heated anti-inhibitor coagulant complex in haemophilia patients. Transfusion 1990;30:626-30
   PubMed Web of Science ®Google Scholar
• Key NS, on behalf of the US rFVIIa Home Therapy Study Group. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-18
   PubMed Web of Science ®Google Scholar
• Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl 1998;63:24-7
   PubMedGoogle Scholar
• Schonfield S, Reid R. High cost patients and the consortium approach. Pathophysiology and Haemostasis of Thrombosis 2002;32 (Suppl. 1):26-8
   PubMed Web of Science ®Google Scholar
• Brackmann HH, Lenk H, Scharrer I, et al. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999;5:203-6
   PubMed Web of Science ®Google Scholar
• Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006;133:591-605
   PubMed Web of Science ®Google Scholar
• Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, et al. Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 1995;86:983-8
   PubMed Web of Science ®Google Scholar
• Mariani G, Ghirardini A, Bellocco R. Immune tolerance in haemophilia-principal results from the International Registry. Report of the factor VIII and IX Sub-committee. Thromb Haemost 1994;72:155-8
   Web of Science ®Google Scholar
• Kreuz W, Becker S, Lenz E, et al. Factor VIII inhibitors in patients with haemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Semin Thromb Hemost 1995;21:382-9
   PubMed Web of Science ®Google Scholar
• Mariani G, Kroner BL. International Immune Tolerance Registry, 1997 update. Vox Sang 1999;77 (Suppl. 1):25-7
   PubMed Web of Science ®Google Scholar
• DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia 1998;4:568-73
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003;9:436-63
   PubMed Web of Science ®Google Scholar
• DiMichele DM. Immune tolerance therapy dose as an outcome predictor. Haemophilia 2003;9:382-6
   PubMed Web of Science ®Google Scholar
• Ghirardini A, Puopolo M, Chiarotti F, et al. The international registry of immune tolerance: 1994 update. Vox Sang 1996;70 (Suppl. 1):42-6
   PubMed Web of Science ®Google Scholar
• DiMichele DM, Kroner BL, and the ISTH Factor VIII/IX Subcommittee. Analysis of the North American Immune Tolerance Registry (1993–97): current practice implications. Vox Sang 1999;77(Suppl. 1):31-2
   PubMedGoogle Scholar
• Colowick AB, Bohn RL, Avom J, et al. Immune tolerance induction in haemophilia patients with inhibitors: costly can be cheaper. Blood 2000;96:1698-702
   PubMed Web of Science ®Google Scholar
• Bastida E, Mitchell J, Savidge G. Successful immune tolerance induction in a high-responding Factor VIII inhibitor haemophilia a patient treated with FVIII/VWF plasma-derived concentrate, Fanhdi®. Cost effectiveness analysis. J Thromb Haemost 2005;3 (Suppl. 1):1430
   Google Scholar
• Wight J, Richards M. Very high cost treatment for a single individual: a case report. J Publ Health Med 2003;25(1):4-7
   PubMedGoogle Scholar
• Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999;77 (Suppl. 1):33-7
   PubMed Web of Science ®Google Scholar
• DiMichele DM. Immune tolerance: critical issues of factor dose, purity and treatment complications. Haemophilia 2006;12(Suppl. 6):81-5; disscusstion 85-6
   PubMed Web of Science ®Google Scholar
• Mariani G, Kroner B. Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001;86:1186-93
   PubMed Web of Science ®Google Scholar
• Smith MP, Spence KJ, Waters EL, et al. Immune tolerance therapy for haemophilia A patients with acquired factor VIII allo-antibodies: comprehensive analysis of experience in a single institution. Thromb Haemost 1999;81:35-8
   PubMed Web of Science ®Google Scholar
• Rocino A, DiBiasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients. Vox Sang 1999;77(Suppl. 1):65-9
   PubMed Web of Science ®Google Scholar
• Kreuz W, Mentzer D, Auerswald G, et al. Successful immune tolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia 1996;2 (Suppl. 1):19
   Google Scholar
• Lenk H and the Study Group of German Haemophilia Centres. The German National Immune Tolerance Registry, 1997 update. Vox Sang 1999;77 (Suppl. 1):28-30
   Web of Science ®Google Scholar
• Kasper CK. Effect of prothrombin complex concentrates on factor VIII inhibitor levels. Blood 1979;54:1358-68
   PubMed Web of Science ®Google Scholar
• Laurian Y, Girma JP, Lambert T, et al. Incidence of immune responses following 102 infusions of autoplex in 18 haemophilic patients with antibody to factor VIII. Blood 1984;63:457-62
   PubMed Web of Science ®Google Scholar
• Lozier JN, Santagostino E, Kasper CK, et al. Use of porcine factor VIII for surgical procedures in haemophilia A defpatients with inhibitors. Semin Hematol 1993;30(2 Suppl. 1):10-21
   PubMed Web of Science ®Google Scholar
• Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999;5(Suppl. 3):11-17
   PubMed Web of Science ®Google Scholar
• d’Oiron R, Volot F, Reynaud J, et al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate haemophilia A and inhibitors. Semin Hematol 2006;43 (1 Suppl. 1):S3-9
   PubMed Web of Science ®Google Scholar
• Immune Tolerance Induction Study, 2007. Available at: http://www.itistudy.com/Protocol_introduction.asp [Last accessed 3 August 2007]
   Google Scholar
• DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations 1. Haemophilia 2007;13 (Suppl. 1):1-22
   PubMed Web of Science ®Google Scholar
• Gringeri G, Mantovani LG, Scalone L, et al., for the COCIS Study Group. Cost of care and quality of life for patients with haemophilia complicated by Inhibitors: the COCIS Study Group. Blood 2003;102(7):2358-63
   PubMed Web of Science ®Google Scholar
• Guidelines on adverse drug reactions, 2000. Available at: http://www.fda.org [Last accessed 3 August 2007]
   Google Scholar